denotes an abstract that is clinically relevant.
denotes that this is a recommended PHD Trainee Session.
denotes that this is a ticketed session.Session: Plenary Scientific Session
Hematology Disease Topics & Pathways:
Acute Myeloid Malignancies, AML, Research, Clinical Practice (Health Services and Quality), Clinical Research, Health outcomes research, Health disparities research, Diseases, Treatment Considerations, Biological therapies, Real-world evidence, Myeloid Malignancies, Transplantation (Allogeneic and Autologous)
We have previously shown that age, comorbidity burden, cytogenetic risk, and geriatric health significantly impact the likelihood of receiving allo-HCT and mortality among AML patients (pts). Building on these findings, we now examine the role of socioeconomic status (SES) as determined by the areas where participants lived within the same study cohort, focusing on the receipt of allo-HCT and post-transplant mortality.
Methods:
Here we report results of a prospective, multi-center observational study across 13 predominantly academic centers enrolling adult AML pts. We examined the following SES factors as estimated by the zip codes in which pts lived: median household income; % of adults aged ≥25 years with < a high school education or equivalent (i.e., General Education Diploma); % of households below the poverty level; % of households receiving Supplemental Nutrition Assistance Program (SNAP)/food stamps; % of occupied housing units (rented and owner-occupied) where 30% or more of income is spent on housing; % of owner-occupied housing units with a mortgage that have either a second mortgage, home equity loan or both; % of households receiving Supplemental Security Income (SSI, disability); and % of people working for pay who drive to work alone. Fine-Gray regression models were used to evaluate factors influencing the receipt of HCT, where death without HCT was treated as a competing risk. For overall mortality after HCT, Cox regression with left truncation at HCT was employed. All SES factors were modeled as continuous linear variables, with hazard ratio (HR) presented in terms of an increase in income of $25,000 and an increase in % of other factors of 10%. Additionally, each SES model was adjusted for age, Hematopoietic Cell Transplant-specific Comorbidity Index, disease status, European LeukemiaNet risk, Karnofsky Performance Scale, Patient Health Questionnaire-9, Activities of Daily Living, 4-Meter Walk Test, and Functional Assessment of Cancer Therapy.
Results:
In our analysis of 695 AML pts, a multivariable analysis showed a decrease in the likelihood of HCT receipt by 32% as the percentage of residents with less than a high school education in a neighborhood increased by 10% (HR: 0.68; 95% CI, 0.55-0.84, p=0.0005). We also observed a 14% decrease in the likelihood to receive allo-HCT for each 10% increase in households receiving SNAP compared to baseline levels (HR=0.86; 95% CI, 0.74-1.00, p=0.04). On the other hand, increase in the likelihood of HCT receipt was modest (5%) as median area income increased by $25,000 compared to areas with baseline median income (HR: 1.05; 95% CI, 0.94-1.18, p=0.39). There was also a small decrease (15%) in the likelihood of HCT receipt for each 10% increase in percentage of households below the poverty level (HR=0.85; 95% CI, 0.70-1.03, p=0.10) but a larger decrease (34%) for each 10% increase in households receiving SSI (HR=0.66; 95% CI, 0.39-1.11, p=0.11).
There was little evidence of an association between median area income and overall mortality after HCT (HR: 0.97; 95% CI, 0.57-1.66, p=0.92). There was a numerical increased hazard of mortality after HCT as the percentage of residents with less than a high school education in a neighborhood increased by 10%, but the increase was modest (HR: 1.14; 95% CI, 0.66-1.98, p=0.64), little evidence of an increase or decrease in mortality as the percentage of households below the poverty level increased by 10% (HR=0.98; 95% CI, 0.61-1.57, p=0.92), and numerical (but modest) increases in mortality as the percentage of households receiving SNAP increased by 10% (HR=1.10; 95% CI, 0.77-1.57, p=0.60), and as the percentage of households receiving SSI increased by 10% (HR=1.23; 95% CI, 0.73-1.29, p=0.40).
Conclusion:
These findings underscore potential impact of socioeconomic disparities on receipt of HCT in AML pts. Lower educational attainment could be a barrier to receiving HCT. This suggests the primary issue is access to HCT, as SES does not seem to definitively affect post-transplant outcomes among those who receive HCT. This highlights the need for targeted interventions to improve access to HCT for pts from lower socioeconomic backgrounds. Efforts should focus on addressing financial barriers, improving health literacy, and enhancing support systems to ensure equitable access to life-saving treatments. These are some of the key focuses of the ACCESS initiative by the ASTCT and NMDP (Auletta, TCT 2022).
Disclosures: Wuliji: Mustang BIo: Membership on an entity's Board of Directors or advisory committees. Gerds: Agios: Consultancy; Disc Medicine: Consultancy; PharmaEssentia: Consultancy; Rain Oncology: Consultancy; GSK: Consultancy; AbbVie: Consultancy; BMS: Consultancy. Medeiros: Abbvie, AstraZenaca: Current equity holder in publicly-traded company; AstraZenaca: Current Employment. Shami: Chimerix, Inc.: Other: grant; Amgen: Other: grant; Abcuro, Inc.: Other: grant; Bristol Myers Squibb: Membership on an entity's Board of Directors or advisory committees; Daiichi Sankyo, Inc.: Membership on an entity's Board of Directors or advisory committees; Gilead Sciences, Inc.: Membership on an entity's Board of Directors or advisory committees; Takeda Pharmaceuticals: Membership on an entity's Board of Directors or advisory committees; RJH BioSciences: Membership on an entity's Board of Directors or advisory committees; JSK Therapeutics: Other: Chief Medical Officer and serves on the Board of Directors ; National Cancer Network: Other: leadership role; US Patents: Patents & Royalties: holds US Patents (8,404,665; 9,005,656). Galvin: Incyte Corporation: Current Employment, Current equity holder in publicly-traded company. Luger: Marker Therapeutics: Membership on an entity's Board of Directors or advisory committees; Daiichi Sankyo: Membership on an entity's Board of Directors or advisory committees; Takeda: Research Funding; Novartis: Consultancy, Membership on an entity's Board of Directors or advisory committees; Amgen: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; AbbVie: Membership on an entity's Board of Directors or advisory committees; Astellas: Consultancy. Wildes: Janssen: Consultancy; Sanofi: Consultancy; Pfizer: Consultancy. Wang: Takeda: Consultancy, Membership on an entity's Board of Directors or advisory committees; Dava Oncology: Speakers Bureau; Amgen: Membership on an entity's Board of Directors or advisory committees; PharmaEssentia: Consultancy, Membership on an entity's Board of Directors or advisory committees; NuProbe: Consultancy, Membership on an entity's Board of Directors or advisory committees; Pfizer: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; CTI Biopharma: Membership on an entity's Board of Directors or advisory committees; Blueprint: Membership on an entity's Board of Directors or advisory committees; Jazz: Consultancy, Membership on an entity's Board of Directors or advisory committees; Astellas: Consultancy, Speakers Bureau; Novartis: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; UptoDate: Other: Section Editor; Daiichi Sankyo: Membership on an entity's Board of Directors or advisory committees; GlaxoSmithKline: Membership on an entity's Board of Directors or advisory committees; Immunogen: Membership on an entity's Board of Directors or advisory committees; Janssen: Membership on an entity's Board of Directors or advisory committees; J&J: Membership on an entity's Board of Directors or advisory committees; Mana: Membership on an entity's Board of Directors or advisory committees; Qiagen: Membership on an entity's Board of Directors or advisory committees; Rigel: Membership on an entity's Board of Directors or advisory committees; Schrodinger: Membership on an entity's Board of Directors or advisory committees; Sellas: Membership on an entity's Board of Directors or advisory committees; Stemline: Membership on an entity's Board of Directors or advisory committees; Sumitomo Pharma: Membership on an entity's Board of Directors or advisory committees; Syndax: Membership on an entity's Board of Directors or advisory committees; Kura: Speakers Bureau; Kite: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; GSK: Consultancy, Membership on an entity's Board of Directors or advisory committees; Gilead: Consultancy, Membership on an entity's Board of Directors or advisory committees, Other: Data Safety Monitoring Committee, Award Committee, Research Funding; BMS: Consultancy, Membership on an entity's Board of Directors or advisory committees; Abbvie: Consultancy, Membership on an entity's Board of Directors or advisory committees, Other: Data Safety Monitoring Committee, Research Funding, Speakers Bureau. Sekeres: Kurome: Membership on an entity's Board of Directors or advisory committees; Schroedinger: Membership on an entity's Board of Directors or advisory committees; Bristol Myers Squibb: Membership on an entity's Board of Directors or advisory committees, Research Funding. Appelbaum: Incyte: Honoraria. Percival: BMS/Celgene: Research Funding; VinceRx: Research Funding; Oscotec: Research Funding; Cardiff Oncology: Research Funding; Immunogen: Research Funding; Trillium: Research Funding; Nohla Therapeutics: Research Funding; Glycomimetics: Research Funding; Biosight: Research Funding; Telios: Research Funding; Pfizer: Research Funding; Abbvie: Research Funding; Astex: Research Funding; Ascentage: Research Funding. Sandmaier: Actinium Pharmaceuticals: Other: Attended Advisory Board Meeting; Royalty agreement with employer (Fred Hutch. Sorror: JAZZ pharmaceuticals: Consultancy, Honoraria.